Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis
NCT ID: NCT07078435
Last Updated: 2025-09-02
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
NA
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-09
Study Completion Date
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Endometriosis is a chronic inflammatory, polygenic, and multifactorial disease affecting approximately 10% of women of reproductive age, corresponding to over one million women in France. Endometriosis profoundly impairs the health and quality of life of affected individuals and carries a significant socio-economic burden, making it a major public health concern. To date, the pathogenesis and prognostic factors of disease progression remain poorly understood. Despite current treatment options, which are based on hormonal therapy or surgery, resistance and recurrence are frequent, underscoring the urgent need for innovative therapeutic strategies.
The hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity- within the peritoneal cavity or at distant sites-forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although data remain scarce, the literature points to several key mechanisms:
Inflammation and innate immunity with the dendritic cells, that initiate and orchestrate immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1/M2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles. Natural Killer cells exhibit disrupted expression patterns of activating and degranulation capacity.
Microbiota: Many studies suggest a potential role for the intestinal microbiota in the initiation and/or promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity.
Resolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.
The interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, Natural Killer cells) - in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies that may be of interest in endometriosis.
Study Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.
The primary objective is to identify immune biomarkers associated with endometriosis.
Secondary objectives include:
1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.
2. Characterization of the immunogenetic KIR/HLA (Killer Immunoglobulin-like Receptors / Human Leukocyte Antigen) system in both study groups.
3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.
4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and/or profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.
Study Population:
The study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis, aged 18 to 42.
Study Procedures:
Women in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. For both groups, peripheral blood samples will be collected during routine care and stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.
The hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity- within the peritoneal cavity or at distant sites-forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although data remain scarce, the literature points to several key mechanisms:
Inflammation and innate immunity with the dendritic cells, that initiate and orchestrate immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1/M2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles. Natural Killer cells exhibit disrupted expression patterns of activating and degranulation capacity.
Microbiota: Many studies suggest a potential role for the intestinal microbiota in the initiation and/or promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity.
Resolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.
The interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, Natural Killer cells) - in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies that may be of interest in endometriosis.
Study Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.
The primary objective is to identify immune biomarkers associated with endometriosis.
Secondary objectives include:
1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.
2. Characterization of the immunogenetic KIR/HLA (Killer Immunoglobulin-like Receptors / Human Leukocyte Antigen) system in both study groups.
3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.
4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and/or profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.
Study Population:
The study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis, aged 18 to 42.
Study Procedures:
Women in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. For both groups, peripheral blood samples will be collected during routine care and stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort
NCT06973603
Endometriosis
NOT_YET_RECRUITING
Microbiota and Immunoassay in Women With and Without Endometriosis: a Pilot Study
NCT05433909
Endometriosis
Endometriosis-related Pain
UNKNOWN
NA
The Immune Base of Endometriosis
NCT00370123
Endometriosis
WITHDRAWN
Microbiome and Immunologic Analysis - Women With Endometriosis
NCT04159740
Endometriosis
COMPLETED
Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care
NCT06331676
Endometriosis
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction Endometriosis is a chronic inflammatory, polygenic, and multifactorial disease affecting approximately 10% of women of reproductive age, corresponding to over one million women in France. Endometriosis profoundly impairs the health and quality of life of affected individuals and carries a significant socio-economic burden, making it a major public health concern. To date, the pathogenesis and prognostic factors of disease progression remain poorly understood. Despite current treatment options, which are based on hormonal therapy or surgery, resistance and recurrence are frequent, underscoring the urgent need for innovative therapeutic strategies.
The hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity - within the peritoneal cavity or at distant sites - forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although few data remain, the literature points to several key mechanisms:
Inflammation and Innate Immunity: Dendritic cells (DC), pivotal in initiating and orchestrating immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1/M2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles, with interleukin-8 (IL-8) potentially playing a key role via its angiogenic and chemoattractant properties. Natural Killer (NK) cells exhibit disrupted expression patterns of activating and inhibitory Killer-cell Immunoglobulin-like Receptors (KIRs), alongside diminished IFN - gamma (InterFeroN) secretion and degranulation capacity.
Microbiota: It is now well established that the immune system maintains a dynamic interaction with the gut microbiota at the mucosal barrier, with reciprocal modulation of local and systemic immunity. Furthermore, endometriosis is a hormone-sensitive pathology, and it is noteworthy that microbiota could increase plasma estrogen levels via β-glucuronidase-expressing bacteria. Other link with the microbiota, in mice, the treatment with antibiotics decrease the pathology. It is now well known that the dysbiosis can lead to systemic inflammation and subsequently contribute to inflammatory diseases development. A limited number of studies suggest a potential role for the intestinal microbiota in the initiation and/or promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity and an altered Firmicutes/Bacteroidetes ratio.
Resolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.
The biotechnology company Med'Inn'Pharma has developed a complex pro-resolving biological drug consisting of a macrophage supernatant that has eliminated apoptotic cells. This drug candidate has been used effectively in various experimental models of unresolved chronic inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. In collagen-induced arthritis (a relevant model for rheumatoid arthritis), this drug candidate induces the reprogramming of macrophages towards a pro-resolving profile. The same applies to dendritic cells, with a significant reduction in the expression of costimulatory molecules.
The interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, NK cells)-in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies.
Study Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.
The primary objective is to identify immune biomarkers associated with endometriosis. The primary endpoint is the characterization and comparison of innate immune cells (both tissue-resident and circulating) across different biological compartments (blood, peritoneal fluid, biopsies), and between women with and without endometriosis ("endometriosis" vs "control" groups).
For that, we will perform immunophenotyping using flow cytometry on cells from each tissue (blood, endometrium, peritoneum, peritoneal lavage, and, for the endometriosis group, endometriotic lesions). A panel of approximately twenty fluorochrome-conjugated antibodies will be used to characterize the phenotype and activation status of each cell type within each tissue, including dendritic cells, macrophages, natural killer cells, and other innate immune cells. Cellular functionality will also be assessed by analyzing culture supernatants using the Luminex technique.
Secondary objectives include:
1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.
2. Characterization of the immunogenetic KIR/HLA (Human Leukocyte Antigen) system in both study groups.
3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.
4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and/or profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.
Secondary endpoints include:
1\. Description and comparison of innate immune cell populations (tissue and circulating) based on one-year clinical outcome (favorable vs unfavorable).
Immunogenetic profiling of HLA-A, -B, -C and KIR alleles by Next-Generation Sequencing (NGS), compared between women with and without endometriosis.
Stromal cell analysis:
* Comparison of stromal cell phenotypes, susceptibility to apoptosis, and macrophage efferocytosis capacity (using monocyte-derived macrophages) between cases and controls.
* Assessment of pro-resolutive factors' impact on macrophage efferocytosis.
Gut microbiota profiling:
Comparison of microbial community composition using 16S rDNA sequencing (relative abundances, Shannon and Bray-Curtis indices), and its evolution at 12 months (cases only), in relation to the presence of endometriosis and clinical outcome at one year.
Study Population:
The study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis. Patients should be young (18 to 42 years old) to ensure that, unfortunately, they may have endometriosis with predominantly inflammatory rather than fibrotic lesions. Furthermore, patients must not be undergoing immune modulation with antibiotics or immunosuppressive agents for the purposes of the study.
Study Procedures:
Women in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. These samples are collected by a gynecologic surgeon specialized in endometriosis.
For both groups, peripheral blood samples will be collected during routine care by the nurse and self stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).
No investigational treatment will be administered. But given the extent of biopsies performed during surgery, French legislation classifies this study as a Class 2 interventional study. The study has been approved by an ethics committee in accordance with French regulatory requirements.
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.
The clinical evaluation focus on the medical history, the pain, the treatment. She is realized by surgeon.
All biological samples (blood, biopsies, peritoneal lavage, stool) will be processed and stored (plasma, cells, DNA, tissue) in a dedicated biobank for subsequent analysis. All samples will be collected at CHUGA.
Statistical Analysis
Given the expected sample size, appropriate non-parametric tests will be used. For each group, qualitative variables will be expressed as counts and percentages, and quantitative variables as mean ± standard deviation or median with interquartile range depending on the distribution. Comparisons will be conducted using Friedman, Wilcoxon, Mann-Whitney, or Student's t-tests, depending on data distribution, number of groups, and pairing status. Log-transformation will be applied if normality is not met. Primary comparisons will focus on immune cell parameters across tissues and study groups, including:
* Frequencies of immune cell subsets,
* Activation/maturation status,
* TLR ligand responses,
* KIR/HLA genotype combinations,
* Stromal cell apoptosis,
* Macrophage efferocytosis capacity,
* Gut microbiota composition (α-diversity: Shannon and Simpson indices; β-diversity: Bray-Curtis dissimilarity).
To control for multiple comparisons, Bonferroni correction may be applied. This exploratory study aims to identify candidate biomarkers and immunological signatures associated with endometriosis and disease recurrence, thereby generating hypotheses for future investigations.
Conclusion Endometriosis imposes a substantial burden on affected women and society. While no direct benefit is anticipated for participants, this study aims to advance the understanding of biological-especially immunological-mechanisms underpinning the disease. The results may support the identification of novel therapeutic targets, including agents that promote inflammation resolution. This research will help define an immunological signature of endometriosis, establish links with the gut microbiota, and assess the preclinical efficacy of a pro-resolutive biologic compound as a potential disease-modifying therapy.
The hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity - within the peritoneal cavity or at distant sites - forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although few data remain, the literature points to several key mechanisms:
Inflammation and Innate Immunity: Dendritic cells (DC), pivotal in initiating and orchestrating immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1/M2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles, with interleukin-8 (IL-8) potentially playing a key role via its angiogenic and chemoattractant properties. Natural Killer (NK) cells exhibit disrupted expression patterns of activating and inhibitory Killer-cell Immunoglobulin-like Receptors (KIRs), alongside diminished IFN - gamma (InterFeroN) secretion and degranulation capacity.
Microbiota: It is now well established that the immune system maintains a dynamic interaction with the gut microbiota at the mucosal barrier, with reciprocal modulation of local and systemic immunity. Furthermore, endometriosis is a hormone-sensitive pathology, and it is noteworthy that microbiota could increase plasma estrogen levels via β-glucuronidase-expressing bacteria. Other link with the microbiota, in mice, the treatment with antibiotics decrease the pathology. It is now well known that the dysbiosis can lead to systemic inflammation and subsequently contribute to inflammatory diseases development. A limited number of studies suggest a potential role for the intestinal microbiota in the initiation and/or promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity and an altered Firmicutes/Bacteroidetes ratio.
Resolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.
The biotechnology company Med'Inn'Pharma has developed a complex pro-resolving biological drug consisting of a macrophage supernatant that has eliminated apoptotic cells. This drug candidate has been used effectively in various experimental models of unresolved chronic inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. In collagen-induced arthritis (a relevant model for rheumatoid arthritis), this drug candidate induces the reprogramming of macrophages towards a pro-resolving profile. The same applies to dendritic cells, with a significant reduction in the expression of costimulatory molecules.
The interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, NK cells)-in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies.
Study Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.
The primary objective is to identify immune biomarkers associated with endometriosis. The primary endpoint is the characterization and comparison of innate immune cells (both tissue-resident and circulating) across different biological compartments (blood, peritoneal fluid, biopsies), and between women with and without endometriosis ("endometriosis" vs "control" groups).
For that, we will perform immunophenotyping using flow cytometry on cells from each tissue (blood, endometrium, peritoneum, peritoneal lavage, and, for the endometriosis group, endometriotic lesions). A panel of approximately twenty fluorochrome-conjugated antibodies will be used to characterize the phenotype and activation status of each cell type within each tissue, including dendritic cells, macrophages, natural killer cells, and other innate immune cells. Cellular functionality will also be assessed by analyzing culture supernatants using the Luminex technique.
Secondary objectives include:
1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.
2. Characterization of the immunogenetic KIR/HLA (Human Leukocyte Antigen) system in both study groups.
3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.
4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and/or profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.
Secondary endpoints include:
1\. Description and comparison of innate immune cell populations (tissue and circulating) based on one-year clinical outcome (favorable vs unfavorable).
Immunogenetic profiling of HLA-A, -B, -C and KIR alleles by Next-Generation Sequencing (NGS), compared between women with and without endometriosis.
Stromal cell analysis:
* Comparison of stromal cell phenotypes, susceptibility to apoptosis, and macrophage efferocytosis capacity (using monocyte-derived macrophages) between cases and controls.
* Assessment of pro-resolutive factors' impact on macrophage efferocytosis.
Gut microbiota profiling:
Comparison of microbial community composition using 16S rDNA sequencing (relative abundances, Shannon and Bray-Curtis indices), and its evolution at 12 months (cases only), in relation to the presence of endometriosis and clinical outcome at one year.
Study Population:
The study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis. Patients should be young (18 to 42 years old) to ensure that, unfortunately, they may have endometriosis with predominantly inflammatory rather than fibrotic lesions. Furthermore, patients must not be undergoing immune modulation with antibiotics or immunosuppressive agents for the purposes of the study.
Study Procedures:
Women in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. These samples are collected by a gynecologic surgeon specialized in endometriosis.
For both groups, peripheral blood samples will be collected during routine care by the nurse and self stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).
No investigational treatment will be administered. But given the extent of biopsies performed during surgery, French legislation classifies this study as a Class 2 interventional study. The study has been approved by an ethics committee in accordance with French regulatory requirements.
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.
The clinical evaluation focus on the medical history, the pain, the treatment. She is realized by surgeon.
All biological samples (blood, biopsies, peritoneal lavage, stool) will be processed and stored (plasma, cells, DNA, tissue) in a dedicated biobank for subsequent analysis. All samples will be collected at CHUGA.
Statistical Analysis
Given the expected sample size, appropriate non-parametric tests will be used. For each group, qualitative variables will be expressed as counts and percentages, and quantitative variables as mean ± standard deviation or median with interquartile range depending on the distribution. Comparisons will be conducted using Friedman, Wilcoxon, Mann-Whitney, or Student's t-tests, depending on data distribution, number of groups, and pairing status. Log-transformation will be applied if normality is not met. Primary comparisons will focus on immune cell parameters across tissues and study groups, including:
* Frequencies of immune cell subsets,
* Activation/maturation status,
* TLR ligand responses,
* KIR/HLA genotype combinations,
* Stromal cell apoptosis,
* Macrophage efferocytosis capacity,
* Gut microbiota composition (α-diversity: Shannon and Simpson indices; β-diversity: Bray-Curtis dissimilarity).
To control for multiple comparisons, Bonferroni correction may be applied. This exploratory study aims to identify candidate biomarkers and immunological signatures associated with endometriosis and disease recurrence, thereby generating hypotheses for future investigations.
Conclusion Endometriosis imposes a substantial burden on affected women and society. While no direct benefit is anticipated for participants, this study aims to advance the understanding of biological-especially immunological-mechanisms underpinning the disease. The results may support the identification of novel therapeutic targets, including agents that promote inflammation resolution. This research will help define an immunological signature of endometriosis, establish links with the gut microbiota, and assess the preclinical efficacy of a pro-resolutive biologic compound as a potential disease-modifying therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Endometriosis
Immunity
Microbiota
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
PARALLEL
This study is a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.
Given the extent of the biopsies performed during surgery, which exceed standard care, French legislation classifies this study as a Class 2 interventional study.
Women in the endometriosis group will undergo collection during surgery with endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage during the gynecology surgery.
For both groups, peripheral blood samples will be collected during routine care and stool samples obtained. For the endometriosis group, a second stool sample will be collected at 12 months.
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery.
Given the extent of the biopsies performed during surgery, which exceed standard care, French legislation classifies this study as a Class 2 interventional study.
Women in the endometriosis group will undergo collection during surgery with endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage during the gynecology surgery.
For both groups, peripheral blood samples will be collected during routine care and stool samples obtained. For the endometriosis group, a second stool sample will be collected at 12 months.
A clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endometriosis group
Patients in "endometriosis group" are aged 18-42 years and suffer symptomatic endometriosis that requires a surgery indication (due to persistent symptoms despite medical treatment and/or risk of organ damage). These patients generally undergo hormonal therapy, but this must be discontinued at least one month prior to surgery. The surgery is scheduled to take place during the luteal phase.
Patients don't take a immunosuppressor, antibiotic or present inflammatory bowel disease, recent infection, pregnancy
Group Type
ACTIVE_COMPARATOR
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Intervention Type
PROCEDURE
The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
Blood test
Intervention Type
BIOLOGICAL
Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
Stool samples
Intervention Type
BIOLOGICAL
Before the surgery, the patient will take a stool sample.
Stool samples
Intervention Type
BIOLOGICAL
After 1 year's follow-up, the patient will take a stool sample.
Control group
Patients in "control group" are aged 18-42 years and don't suffer endometriosis that requires a gynecological surgery indication (permanent contraception, benine surgery). The surgery is scheduled to take place during the luteal phase. Patients don't take a immunosuppressor, antibiotic or present inflammatory bowel disease, recent infection, pregnancy
Group Type
ACTIVE_COMPARATOR
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
Intervention Type
PROCEDURE
The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
Blood test
Intervention Type
BIOLOGICAL
Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
Stool samples
Intervention Type
BIOLOGICAL
Before the surgery, the patient will take a stool sample.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
The surgery is performed on both arms as part of the current / recommended treatment. But during this surgery, an extension of the samples is performed. In both arms, the surgeons take samples of the endometrium, peritoneum and peritoneal lavage. For patients with endometriosis, the lesion is also sampled.
Intervention Type
PROCEDURE
Blood test
Before surgery, the patient will need a blood test at the recommendation of the anaesthetist. This allows us to see the level of oestrogen and progesterone in the blood.
Intervention Type
BIOLOGICAL
Stool samples
Before the surgery, the patient will take a stool sample.
Intervention Type
BIOLOGICAL
Stool samples
After 1 year's follow-up, the patient will take a stool sample.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women aged 18-42 years.
* Surgery scheduled during the luteal phase.
* Written informed consent provided.
* Women with confirmed endometriosis and a surgical indication (due to persistent symptoms despite medical treatment and/or risk of organ damage).
* Hormonal therapy discontinued at least one month prior to surgery.
* Absence of isolated ovarian endometrioma.
\- Women requiring benign gynecological surgery with no clinical or intraoperative evidence of endometriosis.
* Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other autoimmune disorders (e.g., lupus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, spondyloarthritis),
* Use of antibiotics within the month prior to surgery,
* Recent infection (\<2 weeks),
* Ongoing treatment with biologics or immunosuppressants,
* Contraindication to surgery due to general condition or comorbidities,
* Hormonal therapy within the month prior to surgery,
* Abdominopelvic surgery involving peritoneal breach within the previous 6 months,
* Pregnancy or breastfeeding,
* Participation in another clinical study (RIPH 1 or 2).
* Surgery scheduled during the luteal phase.
* Written informed consent provided.
* Women with confirmed endometriosis and a surgical indication (due to persistent symptoms despite medical treatment and/or risk of organ damage).
* Hormonal therapy discontinued at least one month prior to surgery.
* Absence of isolated ovarian endometrioma.
\- Women requiring benign gynecological surgery with no clinical or intraoperative evidence of endometriosis.
* Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other autoimmune disorders (e.g., lupus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, spondyloarthritis),
* Use of antibiotics within the month prior to surgery,
* Recent infection (\<2 weeks),
* Ongoing treatment with biologics or immunosuppressants,
* Contraindication to surgery due to general condition or comorbidities,
* Hormonal therapy within the month prior to surgery,
* Abdominopelvic surgery involving peritoneal breach within the previous 6 months,
* Pregnancy or breastfeeding,
* Participation in another clinical study (RIPH 1 or 2).
Exclusion Criteria
* Intraoperative impossibility to perform surgery due to local conditions with an unfavorable benefit-risk balance for the patient.
* Discovery of endometriosis during surgery in the control group.
* Use of biologics or immunosuppressants within the first year after inclusion in the endometriosis group.
* Antibiotic use in the month preceding the second stool sample (endometriosis group).
* Discovery of endometriosis during surgery in the control group.
* Use of biologics or immunosuppressants within the first year after inclusion in the endometriosis group.
* Antibiotic use in the month preceding the second stool sample (endometriosis group).
Minimum Eligible Age
18 Years
Maximum Eligible Age
42 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Etablissement Français du Sang
OTHER
Sponsor Role
collaborator
University Hospital, Grenoble
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurence Chaperot, PhD
Role: STUDY_DIRECTOR
Etablissement Français du Sang
Thierry Michy, Dortor
Role: PRINCIPAL_INVESTIGATOR
Centre Universitaire Grenoble Alpes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHUGA
Grenoble, Isère, France
Site Status
Countries
Review the countries where the study has at least one active or historical site.
France
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC25.0052
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients
NCT06897436
NOT_YET_RECRUITING
ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis
NCT01301885
RECRUITING
Diagnostic and Prognostic Markers of Endometriosis in Menstrual Blood
NCT06245512
RECRUITING
EndometrioSis PRediction and Assessment of InflammaTion
NCT07114081
COMPLETED
The Effectiveness of Laparoscopic Treatment of Superficial Endometriosis for Managing Chronic Pelvic Pain
NCT04081532
COMPLETED
NA
Endometriosis Transcriptomic Cell Atlas
NCT06502548
RECRUITING
NA
Study of the Prevalence of Endometriosis and Adenomyosis
NCT06211569
RECRUITING
The Developmental Origins of Endometriosis
NCT05951452
RECRUITING
Quality of Life and Fertility of Patient With Deep Surgical Endometriosis: a Prospective Cohort
NCT03555903
RECRUITING
Efficacy of Cryoablation of Abdominal Wall Endometriosis
NCT03627676
UNKNOWN
NA
Cohort of the Franco-European Multidisciplinary Institute of Endometriosis
NCT07243587
RECRUITING
Sexual Health After Endometriosis Surgery
NCT03901885
COMPLETED
NA
Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies: This is an Observational Study Aimed at Shedding Light on Women's Health
NCT06990971
NOT_YET_RECRUITING
Perinatal Consequences of Endometriosis
NCT02498691
COMPLETED
NA
National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis
NCT06356831
RECRUITING
Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO)
NCT05339451
RECRUITING
Endometriosis and Pain
NCT03993197
COMPLETED
NA
ENDometriosis: Evaluation of Detection and Need for ALGOlogic Care Before Surgery
NCT06997809
NOT_YET_RECRUITING
NA
Incidence of Different Surgical Technics for Colorectal Deep Infiltrating EndoMetriosis on the Post-operative Fertility and Pregnancy Outcomes
NCT04681898
COMPLETED
The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Endometriosis
NCT05788952
UNKNOWN
Thoracic Endometriosis: A Cohort Study
NCT05527002
COMPLETED
Endometriosis and Chronic Endometritis
NCT05824507
COMPLETED
NA
A Study on the Correlation Between Endometriosis and Intra-tissue Microbiota
NCT06266897
RECRUITING
Development of a Microbiome Non-invasive Diagnosis Tool
NCT03330444
COMPLETED
Evaluation of miRNAs in Endometriosis
NCT04728152
UNKNOWN